Pre-press HTB reports from BHIVA conference

27 April 2012. Related: News.

PRE-PRESS reports

Hyperlinks below to early reports for the next edition of HTB are published online in draft.

New reports will also be added to this page and hyperlinked next week.

Introduction

This year the BHIVA spring conference was held in Birmingham and as usual it included both important national research and impressive international speakers. In addition to more than 40 oral presentations, the meeting included case studies and over 230 posters.

The selection of below only highlights some of these studies. For further details please contact the researchers directly.

The abstracts from the conference are available free online as PDF supplements to the April edition of HIV Medicine.

http://onlinelibrary.wiley.com/doi/10.1111/hiv.2012.13.issue-s1/issuetoc

As with previous years, some of these sessions will be available as webcasts and some of the slide presentations can already be viewed or downloaded from the conference website.

http://www.bhiva.org/Presentations120418.aspx

Reports in this issue include:

• Half of gay men in London interested in daily PrEP to reduce risk of HIV
• Recent infections common in UK; 30% gay men aged 15-25 infected within a year of diagnosis
• One third of HIV positive people at five UK clinics have symptomatic depression: link to adherence and viral suppression – 40% cases are untreated
• Hodgkins Lymphoma: survival normalises to HIV negative rates despite more advanced disease at diagnosis
• Promising outcomes from laser ablative treatment of AIN2/3 to prevent anal cancer
• KS in the HAART era includes patients with high CD4 and suppressed viral load: importance of KS chemotherapy for some patients in addtion to ART
• 3rd vs 4th generation HIV testing: almost half of UK clinics out of step with national guidelines
• Case reports of complications from ketamine use in two MSM on ritonavir-based combinations
• Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations
• Outcomes from switches to atazanavir/r in London
• Intimate partner violence towards HIV positive women in the UK